MEDFORD, N.Y.--(BUSINESS WIRE)--July 27, 2006--Chembio Diagnostics, Inc. (OTCBB: CEMI - News) has submitted a CLIA waiver application to the United States Food & Drug Administration for the Company’s SURE CHECK® HIV 1/2 rapid diagnostic test. With this application, Chembio has submitted two rapid HIV tests applications for CLIA Waiver during the last few weeks, which, if granted, would expand the Company’s domestic marketing opportunity. The Clinical Laboratory Improvement Amendments of 1988 (CLIA) law established provisions for categorizing a test as waived. Waived tests under CLIA include tests that employ methodologies that are so simple and accurate as to render the likelihood of erroneous results negligible; or that pose no reasonable risk of harm to the patient if the test is performed incorrectly.
